323 related articles for article (PubMed ID: 15243520)
21. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic advances in cutaneous T-cell lymphoma (CTCL): from retinoids to rexinoids.
Stadler R; Kremer A
Semin Oncol; 2006 Feb; 33(1 Suppl 3):S7-10. PubMed ID: 16516669
[TBL] [Abstract][Full Text] [Related]
23. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
24. Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas.
Tancrède-Bohin E; Ionescu MA; de La Salmonière P; Dupuy A; Rivet J; Rybojad M; Dubertret L; Bachelez H; Lebbé C; Morel P
Arch Dermatol; 2004 Sep; 140(9):1057-61. PubMed ID: 15381544
[TBL] [Abstract][Full Text] [Related]
25. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
26. Bexarotene: a clinical review.
Farol LT; Hymes KB
Expert Rev Anticancer Ther; 2004 Apr; 4(2):180-8. PubMed ID: 15056048
[TBL] [Abstract][Full Text] [Related]
27. Phase I/II study of the oral retinoid X receptor agonist bexarotene in Japanese patients with cutaneous T-cell lymphomas.
Hamada T; Sugaya M; Tokura Y; Ohtsuka M; Tsuboi R; Nagatani T; Tani M; Setoyama M; Matsushita S; Kawai K; Yonekura K; Yoshida T; Saida T; Iwatsuki K
J Dermatol; 2017 Feb; 44(2):135-142. PubMed ID: 27543197
[TBL] [Abstract][Full Text] [Related]
28. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma.
Gerami P; Rosen S; Kuzel T; Boone SL; Guitart J
Arch Dermatol; 2008 Jun; 144(6):738-46. PubMed ID: 18559762
[TBL] [Abstract][Full Text] [Related]
29. Bexarotene ligand pharmaceuticals.
Hurst RE
Curr Opin Investig Drugs; 2000 Dec; 1(4):514-23. PubMed ID: 11249708
[TBL] [Abstract][Full Text] [Related]
30. Long-term follow-up of patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-A monotherapy.
Querfeld C; Rosen ST; Kuzel TM; Kirby KA; Roenigk HH; Prinz BM; Guitart J
Arch Dermatol; 2005 Mar; 141(3):305-11. PubMed ID: 15781671
[TBL] [Abstract][Full Text] [Related]
31. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion.
Assaf C; Bagot M; Dummer R; Duvic M; Gniadecki R; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2006 Aug; 155(2):261-6. PubMed ID: 16882161
[TBL] [Abstract][Full Text] [Related]
32. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results.
Duvic M; Hymes K; Heald P; Breneman D; Martin AG; Myskowski P; Crowley C; Yocum RC;
J Clin Oncol; 2001 May; 19(9):2456-71. PubMed ID: 11331325
[TBL] [Abstract][Full Text] [Related]
33. Bexarotene (Targretin) for cutaneous T-cell lymphoma.
Med Lett Drugs Ther; 2000 Apr; 42(1075):31-2. PubMed ID: 10788961
[No Abstract] [Full Text] [Related]
34. Polish Lymphoma Research Group Experience With Bexarotene in the Treatment of Cutaneous T-Cell Lymphoma.
Sokolowska-Wojdylo M; Florek A; Zaucha JM; Chmielowska E; Giza A; Knopinska-Posluszny W; Kulikowski W; Prejzner W; Romejko-Jarosinska J; Paszkiewicz-Kozik E; Osowiecki M; Walewski J; Rogowski W; Grzanka A; Placek W; Lugowska-Umer H; Kowalczyk A; Nowicki R; Jurczak W
Am J Ther; 2016; 23(3):e749-56. PubMed ID: 24732904
[TBL] [Abstract][Full Text] [Related]
35. Follicular mycosis fungoides: successful treatment with oral bexarotene.
Shistik G; Scalf LA; Fenske N; Glass LF
J Drugs Dermatol; 2004; 3(3):301-4. PubMed ID: 15176165
[TBL] [Abstract][Full Text] [Related]
36. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland.
Väkevä L; Ranki A; Hahtola S
Acta Derm Venereol; 2012 May; 92(3):258-63. PubMed ID: 22678563
[TBL] [Abstract][Full Text] [Related]
37. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides).
Kessler JF; Jones SE; Levine N; Lynch PJ; Booth AR; Meyskens FL
Arch Dermatol; 1987 Feb; 123(2):201-4. PubMed ID: 2949706
[TBL] [Abstract][Full Text] [Related]
38. Bexarotene in cutaneous T-cell lymphoma: third retrospective study of long-term cohort and review of the literature.
Quéreux G; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Dréno B
Expert Opin Pharmacother; 2013 Sep; 14(13):1711-21. PubMed ID: 23837676
[TBL] [Abstract][Full Text] [Related]
39. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms.
Duvic M
Clin Lymphoma; 2000 Nov; 1 Suppl 1():S51-5. PubMed ID: 11707865
[TBL] [Abstract][Full Text] [Related]
40. Topical and oral bexarotene.
Schadt CR
Dermatol Ther; 2013; 26(5):400-3. PubMed ID: 24099070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]